



BIOMUNEX

pharmaceuticals

Next Generation Bi- and Multi-specific Antibodies

Overview

June 2019

Dr. Pierre-Emmanuel Gerard, President & CEO

pe.gerard@biomunex.com

Tel: +33 662 680 518


www.biomunex.com

Biomunex: Executive Summary



Biomunex is a biopharmaceutical company focused on the discovery and development of cutting-edge therapeutic bi- and multi-specific antibodies

- Offers innovative treatment options **in immuno-oncology**
- Located in Paris (France), with an office in Cambridge (MA, USA)



Biomunex is developing proprietary BiXAb[®] bi- and multi-specific antibodies and 2 disruptive discovery programs:

- a Tri-specific antibody technology (TriXAb)
- a novel technology for T Cell redirection



Biomunex's proprietary BiXAb[®] platform generates the next generation bi- and multi-specific antibodies, enabling the Turnkey formatting of a BiXAb[®] from any pair of mAbs as building blocks, in less than 3 months



Establishing strategic collaborations with pharmaceutical companies based on:

- **BiXAb[®] proprietary antibody development**
- **BiXAb[®] platform** for generation of bi- & multi-specific antibodies

2019: *Licensing agreement with SANOFI validated the BiXAb Platform*

BiXAb[®] platform fulfills the 4 key properties of an ideal BsAb technology

4 key properties of an ideal BsAb

Fast-design and modularity

Bispecific development with BiXAb[®]

- Any pair of mAbs as building blocks
- Turnkey formatting
- Rapid generation: 2 to 3 months
- Suitable for any therapeutic domain

Excellent drug-like properties

- Binding unchanged from parental Ab
- No aggregation
- Low risk of immunogenicity
- Optimal half-life


Manufacturability and high production yield

- High stability and production yield
- High purity
- Straightforward industrialization




Multi-specific capability & Versatility

- Versatile platform
- Supports tri- and tetra-specific formats

BiXAb[®] Antibodies



Development of proprietary BiXAb[®] antibodies

Oncology Potential Indications	Targets / MoA	Program	Discovery process	Lead development	Regulatory Preclinical (ie. CMC, tox)	Clinical
Hematological malignancies & solid tumors	CD38 & PD-L1	BMX-101 program				
Solid tumors & hematological malignancies	Novel T Cell redirection	BMX-501 program				
Immuno-oncology	Trispecific platform (TriXAb)	BMX-901 program				

Other programs:

- BMX-002: POC of the BiXAb Platform (currently being out-licensed)
- Anti-EGFR family program in pancreatic cancer (grant from the ANR)

Partnerships and M&A transactions in immuno-oncology highlight the value potential of Biomunex

Potential disruptive cancer treatment options based on the BiXAb® platform:

- **BMX-101:** BiXAb for **solid tumors** (ie: colorectal cancer, NSCLC, etc) and **hematological malignancies** (ie: R/R multiple myeloma, etc)
- **BMX-501:** for **solid tumors** (ie: colorectal cancer, hepatic metastasis, etc) and **hematological malignancies** (ie: non-Hodgkin lymphoma, acute (ALL) and chronic lymph. leukemia (CLL), etc)

Potential partnerships for BiXAb® platform based on following examples:

Company	Partner	Platform/Stage	Year	Details
Xencor	Novartis	XmAb BsAb Platform Preclinical	2016	\$150M upfront in addition to up to \$2.41Bn in clinical, regulatory and sales milestones
Pieris	Servier	Protein – Ab chimera platform, preclinical	2017	\$31M upfront + up to \$338M for the 1 st program + up to \$201M for each of the 4+3 potential next ones
Zymeworks	Janssen J&J	Efect BsAb Platform (6 BsaB programs) preclinical	2017	\$50M upfront + up to 282M for the 1 st program + up to \$1,12Bn overall

Potential M&A transactions for Biomunex based on following examples:

- Micromet acquired by Amgen in 2012 for \$ 1.16 Bio
- Covagen acquired by Janssen (Johnson & Johnson) in 2014 for \$ 240 Mio
- Dutalys acquired by Roche in 2014 for nearly \$ 500 Mio


Biomunex is currently establishing 2 types of strategic collaborations for revenues and value creation

1. Development and out-licensing of proprietary BiXAb[®] antibodies for IO

- From discovery through clinical development (Phase II)

2. Strategic collaboration deals based on the BiXAb[®] platform

- BiXAb[®] Partnerships
- TriXAb trispecific platform and non-CD3 T Cell redirection platform



Expected Revenues: upfront, milestone payments, royalties on sales

- ❖ Jan. 2019: Biomunex signed a **licensing agreement with Sanofi** for the development of bi- and multi-specific antibodies => **validation of the BiXAb[®] Platform**

Fundraising:

Biomunex will be raising funds in the near future to increase collaborations, develop disruptive proprietary programs and expand the BiXAb[®] platform